



GP-TCM RA Elections - President-Elect and Members of Board of Directors (2025-2026)

With the approval of the current GP-TCM RA Board of Directors (BoD), the Secretariat is holding the 7th GP-TCM RA election for **nine** BoD members, **including** President-Elect.

Standing for President-Elect

Prof. Simon Ming Yuen Lee



Self-introduction

Simon Ming Yuen Lee is currently Chair Professor (biomedical science), Department of Food Science and Nutrition, and Research Centre for Chinese Medicine Innovation at the Hong Kong Polytechnic University. He is also Adjunct Chair Professor at the State Key Laboratory of Quality Research in Chinese medicine of the Institute of Chinese Medical Sciences at the University of Macau. Simon obtained PhD degree in biochemistry from The Chinese University of Hong Kong. His research interests lie in the discovery of drug-like agents from natural products including small molecule and biologics for use in various therapeutic areas, including oncology and neurodegenerative diseases. His dedication to education and research in the fields of genomics, pharmacology and toxicology has led to over 300 scholarly articles, including Nature Genetics, Nature Communications (4×) and Science Advances. Simon is a life member of Clare Hall, University of Cambridge. He has served as a committee member for different professional associations (Chair of Council, Macau Pharmacology Association; Chinese Medicine Regulatory Advisory Board, Pharmaceutical Administration Bureau of Macao SAR government; Technical Expert of Accreditation Assessment for the Innovation and Technology Commission of Hong Kong SAR government).

Personal statement: Why do you apply for the position? What will you do if elected?

As a current BoD member and Secretary-General of the GP-TCM RA, I am committed to serving GP-TCM RA by providing support to the president and working closely with our secretariat. My experience editing of our bi-monthly newsletter has allowed me to focus on communication and engagement within our members and other researchers interested in good practice research in TCM, and I am eager to continue this role as a BoD member. Having co-hosted an annual meeting, I understand the importance of organizing workshops and meetings to gain publicity for GP-TCM RA to attract members so that more talents can join us in advocating good practice research in TCM globally.

I wish to continue this role as a BoD member and extend my efforts as President-Elect of GP-TCM RA. I believe my extensive background in biomedical science, pharmacology, and TCM-related research, as well as my active participation in various professional associations, equips me with the leadership skills necessary for this position. My connections with biotech start-ups and TCM-related corporations can enhance our network, fostering partnerships that will elevate the impact of GP-TCM RA.

Standing for positions on the Board of GP-TCM RA

The following candidates are listed according to the alphabetical order of their surnames.

1. Professor Rudolf Bauer



Self-introduction

Studied pharmacy at University of Munich; Ph.D. in 1984; 1993-2002 associate professor at the Institute of Pharmaceutical Biology, University of Düsseldorf; since 2002 professor of pharmacognosy at University of Graz, Austria; 2004 – 2020 Head of Institute of Pharmaceutical Sciences at University of Graz; since 2008 head of TCM Research Center Graz / Medicinal plant research. Guest professor at School of Chinese Materia Medica, Beijing University of Chinese Medicine; Guangxi Botanical Garden of Medicinal Plants and Institute of Guangxi Medicinal Plants, Nanning; Institute of Medicinal Plant Development, China Academy of Medical Sciences, Beijing; Chengdu University of TCM; Heilongjiang University of CM, Harbin; Changchun University of CM, Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Chinese Medicine, China Medical University, Taichung, Taiwan, and Dr. Kennedy Wong Distinguished Visiting Professorship at School of Chinese Medicine, Hong Kong Baptist University. Recipient of Egon-Stahl-Award of the Society for Medicinal Plant Research (GA), Norman Farnsworth Excellence in Botanical Research Award; Qihuang International Prize of China Association of Chinese Medicine, Outstanding International Scientist Award (Pranab Banerji Memorial Award) of the Society for Ethnopharmacology India (SFE). Honorary doctorates of the universities of Helsinki/Finland and Szeged/Hungary. Recipient of the Government Friendship Award of the Peoples Republic of China. Associate Editor in Chief of Chinese Journal of Natural Medicines and World Journal of Traditional Chinese Medicine (WJTCM). Chairman of the expert group on Chinese herbs and of Group 13A of the European Pharmacopoeia. Previous president of the Society for Medicinal Plant and Natural Products Research (GA) and of the International Society for Ethnopharmacology (ISE). Long experience in natural product chemistry; ca. 420 scientific publications (h-Index = 70).

Personal statement: Why do you apply for the position? What will you do if elected?

I have been committed to best practice in TCM research since more than 30 years, and have always supported the GP-TCM project. I have served for two years as the founding president of GP-TCM Research Association and another two years as past president. During this time, I have been organizing the 2nd annual meeting of GP-TCM RA in Graz in 2013. I have been an active member of the GP-TCM RA Board in the previous period and, and I have acted as chair of the Interest Group "Quality Control". I want to continue serving our Association mainly in the fields of quality control, pharmacological research, and regulatory affairs. I also would like to act as a link of GP-TCM RA to other organizations, like GA, ISE, and the Consortium for the Globalization of Chinese Medicine, in order to establish a powerful network. A further goal is to stimulate international research collaborations in the field of TCM and to tighten the bonds between Europe and China.

2. Mr. Abraham Yu Ling Chan



Self-introduction


As founder and CEO of PuraPharm Corporation, a publicly listed Hong Kong Chinese medicine manufacturer since 1998, I've dedicated my career to modernizing and internationalizing Traditional Chinese Medicine (TCM). Through collaborations with leading international academics, PuraPharm has become a technological leader in TCM, excelling in R&D, manufacturing, marketing, sales, quality control, and basic science research. My commitment to TCM is further evidenced by my advisory roles. I'm a council member of HK Baptist University and advise the Government Chinese Medicines Testing Institute (GCMTI). I also contribute to advisory boards at HK Baptist University's Pharmacy in Chinese Medicine program, Chinese University of Hong Kong's School of Pharmacy, and Hong Kong University's Pharmacy Education program. Internationally, I serve on the Board of the International Society of Oriental Medicine (ISOM) and am the founding director and former president of the Modernize Chinese Medicine International Association (MCMIA). I'm also the advisory board Chairman of the Chinese Medicine Centre jointly established by Western Sydney University and the Beijing University of Chinese Medicine. My credentials include designations as a Chartered Engineer (UK) and Professional Engineer (Ontario,

Canada). www.purapharm.com

Personal statement: Why do you apply for the position? What will you do if elected?

I am applying for a position on the GPTCM board to leverage my extensive experience in modernizing and internationalizing Traditional Chinese Medicine (TCM). My background as founder and CEO of PuraPharm Corporation, a publicly listed TCM manufacturer, coupled with my advisory roles within academic and governmental institutions, positions me uniquely to contribute to the GPTCM's mission. If elected, I will dedicate myself to expanding TCM's global presence by fostering stronger collaborations between industry, academia, and research institutions. Leveraging my established connections within the industry and government, I will champion rigorous quality control standards for Chinese medicine. Furthermore, I will actively disseminate the association's news and research findings to the extensive network of practitioners and acupuncturists connected to PuraPharm worldwide. I believe my proven leadership and commitment to TCM innovation will be invaluable in advancing the GPTCM's goals and promoting the wider understanding and adoption of TCM globally. I am eager to contribute my expertise and passion to this esteemed organization.

3. Dr. Chris Chan



Self-introduction

Chris is the Assistant Professor of the School of Chinese Medicine, HK Baptist University. He designed and conducted multiple clinical trials and cohorts which showed that 1) rehmannia-6-based Chinese medicine and 2) astragalus reduces kidney function decline in diabetes, 3) Chinese medicine was associated with significant mortality reduction in hospitalized COVID, and 4) hospitalized chronic obstructive pulmonary disease. These findings were published in *Kidney Int*, *Clin J Am Soc Nephrol*, *Phytomedicine*, etc. He is also a sub-investigator of a multi-national Chinese medicine industrial trial. He received 23 awards, including the 2018 GP-TCM RA Best Poster Award and 2023 ISCMR Scientific Article Prize.

Chris received training in clinical medicine from HKBU (BCM&BSc, MCM), Tung Wah Group of Hospitals and Guangzhou University of Chinese Medicine (MD); epidemiology and

personalized medicine from London School of Hygiene (MSc Public Health) and UMCG (overseas training); and internal medicine and basic science from Queen Mary Hospital and HKU (PhD). He served for Hospital Authority, WHO and KPMG Advisory on clinical medicine, medical administration, research and policy previously. He serves as a board member of >10 international/local associations in primary care, diabetes, evidence-based medicine and classical literature, and Chinese medicine related policy, hospital, and regulation currently.

Personal statement: Why do you apply for the position? What will you do if elected?

At present, I am the Co-chair of Clinical Practice Guidelines interest group and have been a life member since 2021. I have delivered and organised talks and workshops in trial design and clinical practice guideline for GP-TCM RA since 2019. This year, I would like to take a step forward to serve the GP-TCM RA more as a board member, to contribute further in the daily operation of the organization and foster collaborations internationally.

Given my background in medical administration and clinical trials, I would like to strengthen the connection between 1) academics and industry, and 2) Chinese medicine clinicians and pharmaceutical firms for synergy to better serve the patients. Besides clinical trials, I am also working on medical artificial intelligence in medical education and research (stroke), and would like to explore this area with GP-TCM RA.

Specifically, I will further 1) build an active communication with the interest group members via electronic platforms and extend the membership coverage to a wider academic population, 2) facilitate the development of clinical practice guidelines for integrative medicine for major diseases, and 3) to explore the need and possibility on a new interest group in medical artificial intelligence.

4. Professor Yuan Shiun Chang



Self-introduction

Dr. Yuan Shiun Chang is a professor of Pharmacognosy at China Medical University, Taichung, Taiwan. He received his Ph.D. degree in Pharmacognosy from University of Illinois at Chicago, U.S.A. He had engaged in the quality control studies of TCM herbs. He is the PI of the projects for the compilation of the 2nd, 3rd and 4th editions of both Chinese and English

version of Taiwan Herbal Pharmacopeia (THP). He has also been invited to join Hong Kong Chinese Materia Medica Standard Project, Department of Health, Hong Kong as PI from Taiwan. Professor Chang is nominated as USP HMC East Asia Expert Panel member (EP) and USP Botanical Dietary Supplements and Herbal Medicine Expert Committee (EC). He is also an EDQM TCM Working Party Member, European Pharmacopeia. Professor Chang is also appointed as Honorary Professor of College of Chinese Medicine, Hong Kong Baptist University. Professor Chang was also listed as top 2% world scientists in Stanford University ranking in 2021 on both lifelong and 2021. Professor Chang was elected as Board member of GP TCM RA (2023 - 2024). Professor Chang received Professional Medal from Ministry of Health and Welfare, Taiwan in 2023 for his contribution to the TCM communities. To date, he has published 160 scientific papers and 27 books in TCM related fields. Most of the books were government publications through government research funding.

Personal statement: Why do you apply for the position? What will you do if elected?

Professor Yuan Shiun Chang is a professor of Pharmacognosy at China Medical University, Taichung, Taiwan. He had engaged in the quality control studies of TCM herbs. Since the establishment of GP TCM RA in Europe in 2012, Professor Chang had participated actively in all annual meetings of GP TCM RA. Starting from the first meeting in Leiden, in 2012, 2nd meeting in Graz, Austria in 2013, Nanjing, China, Mons in 2015, Hong Kong in 2016, KEW, UK in 2018, Daegu, Korea in 2019, virtual meeting in 2020, 2021 and 2023, Leiden in 2023 and the last GP TCM RA meeting in Macau in 2024. Professor Chang also work with Professor Qihe Xu and served as Associate editor of the Newsletter of GP TCM RA for a few years. Professor Chang also help to have China Medical University pay the Institute membership fee each year in the past. Professor Chang was elected as Board member of GP TCM RA (2023 - 2024). Professor Chang like to seek nomination as candidate for the GP TCM RA board election for the 2025 – 2026.

If reelected as Board member, Dr. Chang will continue to participate actively in the organization. Dr. Chang will also encourage more colleagues from Taiwan to participated in GP TCM RA annual meeting.

5. Professor Tai-Ping Fan



Self-introduction

As Dean of School of Life & Health Sciences, Fuyao University of Science & Technology in Fuzhou, China since 2024, Tai-Ping is in renaissance of his scientific career, actively pursuing innovative research in developing safe, effective and affordable products from TCM, and further promoting GP-TCM RA's activities in China and Asia.

Tai-Ping served as Secretary-General, President-elect, President and Treasurer of the GP-TCM RA since 2012 and was elected an Honorary Member. He gave a Plenary Lecture "Health and Healing Through Evidence-based Applications of Traditional Medicine" in a United Nations Academic Impact Conference (2015).

His team was the first to demonstrate the Yin and the Yang of ginseng in modulating angiogenesis, and the first to show bioactive dihydroxylated phenolic acids are generated *de novo* as part of a human's defense mechanism against disease, underpinning the scientific basis of ethnopharmacological applications of *Radix Salvia miltiorrhizae*, and highlights the therapeutic potential of such phytochemicals in humans.

"In recognition of his contributions to the health and wellbeing sector through his innovative research on angiogenesis and TCM", Tai-Ping was elected a fellow of The Royal Society of Arts in 2021. His 10-member team also won Second Prize of International Award for Contribution to Chinese Medicine - Achievement Award in Medical Science of the World Federation of Chinese Medicine Societies in 2022.

- Publications <https://scholar.google.co.uk/citations?user=NzK2TBcAAAAJ&hl=en>

Personal statement: Why do you apply for the position? What will you do if elected?

Invited by Dr Qihe Xu of King's College London in 2009, I became a Deputy Coordinator of the GP-TCM Project, focusing on Regulatory framework in R&D of Chinese herbal medicines. Since the founding of the GP-TCM RA in April 2012, I have served as its Secretary-General (2012-2014), President-elect (2015-2016), President (2017-2018) and Past President (2019-2020). Following the premature death of Professor Peter Hylands in June 2019, the BoD appointed me as Treasurer. Despite initial difficulties, we have re-activated our bank account to serve our members more efficiently. With wide-ranging experiences, I am keen to join the BoD for 2025-2026.

If elected, I would like to continue to serve as Treasurer, working closely with President Mei Wang and Secretary-General Simon Lee. Furthermore, I will actively support all BoD members, Newsletter Editors, Chair/Co-chair of Interest Groups. I will reach out to young academics globally and mentor them for future responsibilities, recruiting more Corporate and Institutional Members. In August 2020, I was invited by China Food & Drug Safety Blockchain Special Committee to assemble an international consortium with experts from 22 countries and Greater China. As this consortium's first chairman, I intend to invite new blood to join our Association, further strengthening academic-industry collaboration.

6. Professor George Pak-Heng Leung



Self-introduction

I am George Pak-Heng Leung. I obtained my Bachelor of Pharmacy and PhD from The Chinese University of Hong Kong. After two years of post-doctoral training at the Department of Medicine at Johns Hopkins University, I joined the Department of Pharmacology and Pharmacy at the University of Hong Kong. I am currently an Associate Professor and Interim Head of the Department. I have more than 25 years of experience in pharmacology research. My research focuses on the pharmacology of traditional Chinese Medicine and natural products, particularly in cancer, neurodegeneration and cardiovascular diseases. I have published 150 full-length papers in international scientific journals, including Phytomedicine, Pharmacological Research, British Journal of Pharmacology, and European Journal of Pharmacology. I am the Editorial Board member of the European Journal of Pharmacology, Current Opinion in Pharmacology, PharmaNutrition, and Acta Materia Medica. I am also the Advisory Editorial Board member of the Kaohsiung Journal of Medical Sciences and the Associate Editor of Frontiers in Pharmacology (Cardiovascular and Smooth Muscle).

Personal statement: Why do you apply for the position? What will you do if elected?

I am applying for the position of Board of Director for the GP-TCM RA because I am passionate about promoting the area of Traditional Chinese Medicine and natural products. Having spent over a decade investigating, I have seen directly how rigorous scientific inquiry may improve patient outcomes and broaden our understanding of ancient therapies in

modern situations.

If elected, I hope to use my academic and scientific background to promote collaboration among scholars, practitioners, and policymakers. My goal is to increase the credibility and integration of TCM in the global healthcare system. I intend to initiate and support research programs that meet the highest scientific standards, ensuring our discoveries are robust, reproducible, and effective. In addition, I will endeavour to secure financing possibilities and launch public awareness initiatives to highlight the benefits and scientific achievements of TCM.

By joining the Board of Directors, I pledge to contribute to the strategic direction of GP-TCM RA, promote ethical procedures in TCM research, and advocate for combining traditional and modern medical techniques to provide holistic patient care.

7. Dr. Lei-Fen Shyur



Self-introduction

Dr. Lie-Fen Shyur is a Distinguished Research Fellow in the Agricultural Biotechnology Research Center, Academia Sinica and holds joint professorships at thirteen universities/institutions in Taiwan. Dr. Shyur has several professional roles, such as current President of Taiwan Association of Traditional and Complementary Medicine (TATCM), Board of Directors, Board Committees, and Advisory Board Members at different governmental organizations, such as Ministry of Economic Affairs and Ministry of Health and Welfare, universities, and international/domestic societies. She serves as editorial board member and referee for many international scientific journals. Dr. Shyur's major research focus is to research and development of phytomedicines/phytoagents for aging-associated diseases, including cancers and sarcopenia. The ultimate goal of Dr. Shyur's lab research is to develop plant-based agents for human and animal health care. Dr. Shyur's research achievements include publication of >120 research articles in high-profile and reputed journals (mainly are the corresponding author) and obtained >35 international/Taiwan patents and several national and prestige awards, such as Tien-Der Lee Outstanding BioMedical Award, 3 National Innovation Awards, 2 National Innovation and Advancement Awards, and 1 National Invention and Creation Award, etc. In 2017, Shyur lab received U.S.

Food & Drug Administration (FDA) approval for Zhaohe Cao-based botanical drug as an Investigational New Drug (IND) for cancer therapy.

Personal statement: Why do you apply for the position? What will you do if elected?

As a scientist conducted in modernization of herbal medicine research for more than 25 years, Dr. Shyur realizes although the advancement of this research area is significant in the past two to three decades, it still needs more systematic efforts and devotion from worldwide researchers, Chinese medical practitioners, young scholars, and pharmaceutical company leaders working together to further strengthen the development of evidence-based Chinese or traditional medicines for more popularly practiced and utilized in human society. Dr. Shyur believes GP-TCM RA is an important vehicle and mechanism to facilitate the cross-talks, networks, and collaborations from worldwide members to promote traditional medicine into mainstream medications in near future. Dr. Shyur would like to serve as a BoD member of the GP-TCM RA and work with the President and all BoD members and Chairs/co-Chairs of different IGs for contemplating and facilitating ideas, methods, and approaches for how to further promote traditional medicine into different and greater stages, especially, as the future of hope, to attract and cultivate more and more young talents engaged in traditional medicine R&D.

8. Professor Monique SJ Simmonds OBE, BSc, PhD, DSc, FLS, FBS, FRES, FWIF



Self-introduction

I currently hold the position of Deputy Director of Science (Partnerships), at the Royal Botanic Gardens, Kew. I also head the Commercial Innovation Unit that co-ordinates the scientific research that Kew does with industry. I have over 30 years' experience of research into different aspects of plant and fungal chemistry with an emphasis on the economic value of natural products, including quality control of medicinal plants. My current research focuses on the economic uses of plants/fungi, in particular their potential for use in cosmetics, functional foods and over-the-counter products such as TCM. My work involves studying the chemistry of plants and fungi and evaluating their biological activities. I am also interested in the development of chemical and DNA authentication methods to check the

quality of plant-derived products being sold as medicines, cosmetics and functional foods. I chair the Herbal committee of the British Pharmacopeia and am on the advisory group of the Hong Kong Government Materia Medica committee. I have over 390 publications with a H-index of 78. My key drive is to increase the diversity of quality plants and fungi entering the trade that can support human wellbeing.

Personal statement: Why do you apply for the position? What will you do if elected?

I have been involved in GP-TCM RA since it was established and am committed to see it flourish as an international research association with a presence not only in China and parts of Asia but in Europe and the United Kingdom. I am very aware that in the United Kingdom the study of TCM as part of a University course has declined but the interest in TCM by the general public has increased. Therefore, we need to ensure that the quality of material entering the trade is high. My research has had a focus on different aspects of quality control and I have and would like to continue to play a role in the Quality Control aspects of GP-TCM RA. I also plan to support the President Elect Mei Wang host the 2025 annual meeting of the GP-TCM RA at the Royal Botanic Gardens, Kew. Having a position on the Board will assist me undertake this task. If elected I would continue to support the association meet its objective to improve the guidelines that support best practice in all aspects of traditional Chinese medicine.

9. Professor Xuanbin Wang



Self-introduction

Prof. Xuanbin Wang, PhD, director of Hubei Key Laboratory of Wudang Local Chinese Medicine Research (HBWDCM), and director of Laboratory of Chinese Herbal Pharmacology, Renmin Hospital in Hubei University of Medicine (HBMU), China.

I graduated from Huazhong University of Science and Technology (HUST) and got my PhD degree in 2009. Then I started my academic career focusing on Chinese herbal pharmacology including Taoist medicine—Han unique folk medicine. In 2011-2013, I had worked in School of Chinese Medicine, the University of Hong Kong (HKU) as a research assistant supervised by Prof. Yibin Feng. In 2018, I studied in LMU Grosshadern Hospital

Munich as a visiting scholar co-working with Dr. Minglun Li, vice-director of Department of Radiation Oncology. In November 2023, I was elected as the chairman of Chinese Experimental Pharmacology Branch of China Association of Chinese Medicine (CEPBCACM). My discipline is in the field of Chinese medicines and Taoist folk medicine. I published 161 papers and wrote 12 books (h-index: 25).

I have become life member of GP-TCM RA since July 2017, and BoD member from 2021 to 2024. I have been active in the annual meetings from the 6th to 12th and edited the newsletters as a vice-editor in-chief from 2017-2020, and provided the materials to NL continuously.

Personal statement: Why do you apply for the position? What will you do if elected?

Working in HBMU and HBWDCM, where is in the global Taoist center –Wudang Mountain in Hubei Province, central China, I have been fascinated with Chinese medicine pharmacology and Wudang folk medicine. Because Youyou TU, the Nobel winner of 2015, discovered artemisinin from ancient Taoist work—*Zhou Hou Bei Ji Fang* (Over-the-Counter for Emergency), I think that some mechanisms of Taoist medicines be worth of research, e.g. *Bigu* (fasting). It is my responsibility to attract more research interesting into Taoist medicine in the academic society.

From 2024, I have recommended my student, Mrs. Yingying Guo, to participate the early career affairs of GP-TCM RA. Also, as the chairman of CEPBCACM and a chairman of Chinese Medicine Branch of Hubei Pharmacological Society (CMHBPS), I have established a bridge between the two Chinese associations and GP-TCM RA. In the future, I would like to participate in IGs of Pharmacology and Toxicology and Quality Control as before. I will promote the academic exchange of Chinese medicine between the mainland China and the world, and provide more information to our newsletter.

10. Dr. Qihe Xu



Self-introduction

Dr Qihe Xu, Senior Lecturer in Renal Medicine & Pharmacology; Head, Renal Science & Integrative Chinese Medicine Laboratory; Director of the King's Centre for Integrative Chinese Medicine (CICM) initiative, King's College London (aka King's); Guest Professor of

Chengdu and Beijing Universities of Chinese Medicine; winner of the 2020 Qihuang International Prize, China Association of Chinese Medicine.

After a decade of medical practice in Beijing, I started an academic career in London in 1999. In the early 2000s, I was Secretary-General of the Chinese Students & Scholars Association in the UK and President of the Chinese Life Scientists Society in the UK.

In 2009-2012, I was the PI of the FP7 GP-TCM Project, which founded the GP-TCM RA. As a GP-TCM RA Life Member, I have served on the BoD for five terms. I was Vice-President (2012-2014) and Newsletter Editor-in-chief (2017-2019) and am an Associate Editor-in-chief of WJTCM, the official journal of the Association. I'm also a Co-Chair of the GP-TCM RA's Pharmacology & Toxicology Interest Group.

I am passionate about integrating TCM wisdom into tomorrow's medicine. My research focuses on TCM-inspired studies of kidney diseases, herbal antifibrotics and botanical nephrotoxicity, and my current main endeavour is to lead King's CICM to its official launch by 2029, in time for King's 200th Anniversary celebration.


Personal statement: Why do you apply for the position? What will you do if elected?

GP-TCM RA 2.0 has continued to thrive under the excellent leadership of Prof. Clara Lau and a devoted BoD. I stand for this BoD election to show my continued support of the Association under the presidency of Dr Mei Wang and a new BoD in the coming two years. In the past decade, I have devoted myself to TCM-inspired research and teaching at King's and, through the GP-TCM RA Newsletters and my own work, disseminating and implementing the GP-TCM consensuses (J Ethnopharmacol. 2012;140:458) and the “3Is” principles (integrity, integration and innovation) of the GP-TCM RA (BMC Complement Altern Med. 2013;13:132).

My research has benefited from the GP-TCM collaborations and guidelines (Phytomedicine 2022;100:154049) and has also revealed large gaps in developing and implementing good practice guidelines in TCM research (Phytomedicine 2022;106:154398). Thus, towards the objectives of the GP-TCM RA, many unmet needs remain.

If elected, I will use my expertise and network to help our Association to level up in developing, disseminating and implementing good practices, strengthening our Newsletters and Interest Groups, mobilising and diversifying our membership, and enabling truly engaged interregional, intersectoral and interdisciplinary collaborations.

11. Professor Linda Lidan Zhong



Self-introduction

Linda Lidan Zhong, **MD., Ph.D** is currently Associate Professor and Director of Chinese Medicine and Biomedical Sciences at Nanyang Technological University, Singapore. She has worked in Chinese Medicine education, research, and service for more than 20 years with more than 150 SCI research papers (H-index 27) on clinical studies of Chinese Medicine and Integrative medicine, evidence-based approaches, and epidemiological research.

She has designed and conducted more than 50 clinical studies with broad scope of diseases and interventions and successfully obtained 19 clinical research projects as Principal Investigator and edited 10 books of Chinese Medicine and Integrated Medicine. She is also the co-chair of interest group in Clinical Studies and Board of Director of International Society for Traditional, Complementary & Integrative Medicine Research (ISCMR).

Her research focuses mainly on integrative medicine and globalization of Chinese Medicine. She is also a Visiting Professor of Integrative Medicine Centre, the University of Toronto, and Visiting Fellow of Australian Research Centre for Complementary and Integrative Medicine, the University of Technology Sydney. In 2020, she was awarded a Qi Huang Young Scholar by the State Administration of Traditional Chinese Medicine in recognition of her excellence in clinical practice and studies of Chinese medicine.

Official Website: <https://dr.ntu.edu.sg/cris/rp/rp02083>

Personal statement, Why do you apply for the position? What will you do if elected?

Equipped with Bachelor in Chinese Medicine, Master of Doctor (MD) in integrative and Chinese Medicine in Shanghai University of TCM, and Doctor of Philosophy (PhD) in Chinese Medicine clinical research at the University of Hong Kong (HKU), I have accumulated over 20 years of experience in the field of Chinese Medicine clinical studies and education.

I have also participated in the International Complementary & Integrative Medicine Research Leadership and Capacity Building Program in 2020, which allowed me to broaden my views on integrative medicine and hone my leadership capabilities.

I was appointed as Director and Associate Professor of Chinese Medicine in Nanyang Technological University (NTU) in 2022. I have been appointed as a Committee Member of

Singapore's Ministry of Health and advising on matters related to TCM Research and Development, and "Healthy SG" initiative.

My career encompasses clinical practice, research, and teaching in Shanghai, Hong Kong, Toronto, and Singapore with enough exposure in multiple culture. I apply for this position and would like to contribution to strengthen the collaboration between EU and southeastern Asia in Good Practice of TCM research, especially to build up an international platform of clinical trials.

-- End --